MX2017014846A - Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi -piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-prop ano-1,2-diol. - Google Patents
Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi -piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-prop ano-1,2-diol.Info
- Publication number
- MX2017014846A MX2017014846A MX2017014846A MX2017014846A MX2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A MX 2017014846 A MX2017014846 A MX 2017014846A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridin
- cyclopentyl
- diol
- propane
- ethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000004146 Propane-1,2-diol Substances 0.000 title 1
- 229960004063 propylene glycol Drugs 0.000 title 1
- KJKKMMMRWISKRF-FQEVSTJZSA-N (2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol Chemical compound CC1=C(OC[C@@H](O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 KJKKMMMRWISKRF-FQEVSTJZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a una forma cristalina del compuesto (S)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-iI)-[1,2,4 ] oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1 ,2-diol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015061153 | 2015-05-20 | ||
| PCT/EP2016/061200 WO2016184939A1 (en) | 2015-05-20 | 2016-05-19 | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014846A true MX2017014846A (es) | 2018-02-19 |
| MX373293B MX373293B (es) | 2020-04-23 |
Family
ID=56068887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014846A MX373293B (es) | 2015-05-20 | 2016-05-19 | Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol. |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10385043B2 (es) |
| EP (1) | EP3298008B1 (es) |
| JP (1) | JP6674967B2 (es) |
| KR (2) | KR20200044155A (es) |
| CN (2) | CN107667104B (es) |
| AU (1) | AU2016263472B2 (es) |
| BR (1) | BR112017024785B1 (es) |
| CA (1) | CA2981130C (es) |
| CL (1) | CL2017002822A1 (es) |
| CY (1) | CY1122506T1 (es) |
| DK (1) | DK3298008T3 (es) |
| EA (1) | EA035133B1 (es) |
| ES (1) | ES2770348T3 (es) |
| HR (1) | HRP20200001T1 (es) |
| HU (1) | HUE047646T2 (es) |
| IL (1) | IL255718B (es) |
| LT (1) | LT3298008T (es) |
| MA (1) | MA42107B1 (es) |
| MX (1) | MX373293B (es) |
| MY (1) | MY192358A (es) |
| PH (1) | PH12017502097B1 (es) |
| PL (1) | PL3298008T3 (es) |
| PT (1) | PT3298008T (es) |
| RS (1) | RS59788B1 (es) |
| SG (1) | SG11201708794PA (es) |
| SI (1) | SI3298008T1 (es) |
| TW (1) | TWI711609B (es) |
| UA (1) | UA119818C2 (es) |
| WO (1) | WO2016184939A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3298008B1 (en) | 2015-05-20 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| WO2021148314A1 (en) | 2020-01-20 | 2021-07-29 | Idorsia Pharmaceuticals Ltd | Accelerated elimination of (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| JP2025531208A (ja) | 2022-09-14 | 2025-09-19 | ヴィアトリス アジア パシフィック プライヴェート リミテッド | １型ｉｆｎ介在疾患の治療において使用するためのｓ１ｐ１受容体調節剤 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| ZA917371B (en) | 1990-09-20 | 1992-06-24 | Merrell Dow Pharma | Calcium uptake inhibitors |
| DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
| EP1070080A4 (en) | 1998-03-09 | 2004-12-29 | Smithkline Beecham Corp | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS |
| DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
| ATE307129T1 (de) | 1999-08-19 | 2005-11-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren |
| PL369598A1 (en) | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| JP4709488B2 (ja) | 2002-01-18 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| DE10237883A1 (de) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| WO2004103279A2 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2005014525A2 (en) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Bi-aryl compound having immunosuppressive activity |
| EP1670463A2 (en) | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| CN1894225A (zh) | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| EP2336113A1 (en) | 2004-05-29 | 2011-06-22 | 7TM Pharma A/S | CRTH2 Receptor Ligands for Medical Use |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| CN101043887A (zh) | 2004-10-22 | 2007-09-26 | 默克公司 | 用作s1p受体激动剂的2－(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物 |
| EP2371811B1 (en) | 2004-12-13 | 2014-10-08 | Ono Pharmaceutical Co., Ltd. | Azetidinecarboxylic acid derivative and medicinal use thereof |
| HRP20110613T1 (hr) | 2005-03-23 | 2011-09-30 | Actelion Pharmaceuticals Ltd. | Hidrogenizirani derivati benzo[c] tiofena kao imunomodulatori |
| DE602006003642D1 (en) | 2005-03-23 | 2008-12-24 | Actelion Pharmaceuticals Ltd | Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten |
| CN101180050B (zh) | 2005-03-23 | 2011-07-27 | 埃科特莱茵药品有限公司 | 作为鞘氨醇-1-磷酸盐-1受体激动剂的新颖噻吩衍生物 |
| AU2006232105A1 (en) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| CA2605594A1 (en) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
| JP2008539195A (ja) | 2005-04-26 | 2008-11-13 | ノイロサーチ アクティーゼルスカブ | 新規のオキサジアゾール誘導体及びそれらの医学的使用 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| WO2006135694A2 (en) | 2005-06-10 | 2006-12-21 | Acadia Pharmaceuticals Inc. | Uii-modulating compounds and their use |
| US7951794B2 (en) | 2005-06-24 | 2011-05-31 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives |
| WO2007001973A1 (en) | 2005-06-28 | 2007-01-04 | Astrazeneca Ab | New use |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| KR20080092385A (ko) | 2006-01-24 | 2008-10-15 | 액테리온 파마슈티칼 리미티드 | 신규한 피리딘 유도체 |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP2009527501A (ja) | 2006-02-21 | 2009-07-30 | ユニバーシティ オブ バージニア パテント ファンデーション | Ｓ１ｐ受容体アゴニストとしてのフェニル−シクロアルキル誘導体およびフェニル−複素環誘導体 |
| EP2258700A1 (en) | 2006-05-09 | 2010-12-08 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| MY149853A (en) * | 2006-09-07 | 2013-10-31 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| AR062684A1 (es) | 2006-09-08 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos |
| JP5250556B2 (ja) | 2006-09-21 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | フェニル誘導体及びそれらの免疫調節薬としての使用 |
| EP2081916A1 (en) | 2006-09-29 | 2009-07-29 | Novartis AG | Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties |
| JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
| AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| WO2008151042A1 (en) | 2007-06-01 | 2008-12-11 | American International Group, Inc. | Method and system for projecting catastrophe exposure |
| HRP20110449T1 (hr) | 2007-08-17 | 2011-07-31 | Actelion Pharmaceuticals Ltd. | Derivati piridina kao modulatori receptora s1p1/edg1 |
| MX2010003614A (es) | 2007-10-04 | 2010-04-21 | Merck Serono Sa | Compuestos de diarilo oxadiazol. |
| EP2193125B1 (en) | 2007-10-04 | 2017-01-11 | Merck Serono S.A. | Oxadiazole derivatives |
| ES2449749T3 (es) | 2007-11-01 | 2014-03-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirimidina |
| AU2008326184A1 (en) | 2007-11-08 | 2009-05-14 | Pfizer Inc. | Cyclobutyl carboxylic acid derivatives |
| ES2403209T3 (es) | 2007-12-10 | 2013-05-16 | Actelion Pharmaceuticals Ltd. | Derivados de tiofeno novedosos como agonistas de S1P1/EDG1 |
| US20110046170A1 (en) | 2008-03-06 | 2011-02-24 | Martin Bolli | Novel pyrimidine-pyridine derivatives |
| CA2714665A1 (en) | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridine compounds |
| KR20100125380A (ko) | 2008-03-07 | 2010-11-30 | 액테리온 파마슈티칼 리미티드 | 신규한 아미노메틸 벤젠 유도체 |
| JP5435745B2 (ja) | 2008-03-07 | 2014-03-05 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節剤としてのピリジン−２−イル誘導体 |
| EP2276758B1 (en) * | 2008-03-17 | 2016-01-06 | Bial-Portela & CA, S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol |
| PL2291080T3 (pl) | 2008-05-14 | 2015-12-31 | Scripps Research Inst | Nowe modulatory receptorów sfingozyno-1-fosforanu |
| TW201107302A (en) | 2009-06-26 | 2011-03-01 | Glaxo Group Ltd | Compounds |
| KR101409131B1 (ko) | 2009-07-16 | 2014-06-17 | 액테리온 파마슈티칼 리미티드 | 피리딘-4-일 유도체 |
| WO2012098505A1 (en) | 2011-01-19 | 2012-07-26 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
| US20120214848A1 (en) * | 2011-02-18 | 2012-08-23 | Abbott Laboratories | [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation |
| KR20150021056A (ko) * | 2012-05-22 | 2015-02-27 | 액테리온 파마슈티칼 리미티드 | ２-시클로펜틸-６-메톡시-이소니코틴산의 신규한 제조 방법 |
| EA029309B1 (ru) | 2013-03-15 | 2018-03-30 | Идорсиа Фармасьютиклз Лтд | Производные пиридин-4-ила в качестве агонистов s1p/edg1 |
| EP3298008B1 (en) * | 2015-05-20 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
-
2016
- 2016-05-19 EP EP16724387.2A patent/EP3298008B1/en active Active
- 2016-05-19 UA UAA201712367A patent/UA119818C2/uk unknown
- 2016-05-19 PT PT167243872T patent/PT3298008T/pt unknown
- 2016-05-19 TW TW105115600A patent/TWI711609B/zh active
- 2016-05-19 ES ES16724387T patent/ES2770348T3/es active Active
- 2016-05-19 CN CN201680029127.3A patent/CN107667104B/zh active Active
- 2016-05-19 LT LTEP16724387.2T patent/LT3298008T/lt unknown
- 2016-05-19 HR HRP20200001TT patent/HRP20200001T1/hr unknown
- 2016-05-19 CA CA2981130A patent/CA2981130C/en active Active
- 2016-05-19 SI SI201630640T patent/SI3298008T1/sl unknown
- 2016-05-19 MA MA42107A patent/MA42107B1/fr unknown
- 2016-05-19 BR BR112017024785-2A patent/BR112017024785B1/pt active IP Right Grant
- 2016-05-19 KR KR1020207011402A patent/KR20200044155A/ko not_active Withdrawn
- 2016-05-19 US US15/575,332 patent/US10385043B2/en active Active
- 2016-05-19 SG SG11201708794PA patent/SG11201708794PA/en unknown
- 2016-05-19 PH PH1/2017/502097A patent/PH12017502097B1/en unknown
- 2016-05-19 HU HUE16724387A patent/HUE047646T2/hu unknown
- 2016-05-19 DK DK16724387.2T patent/DK3298008T3/da active
- 2016-05-19 CN CN202210198351.2A patent/CN114573574B/zh active Active
- 2016-05-19 MX MX2017014846A patent/MX373293B/es active IP Right Grant
- 2016-05-19 WO PCT/EP2016/061200 patent/WO2016184939A1/en not_active Ceased
- 2016-05-19 AU AU2016263472A patent/AU2016263472B2/en active Active
- 2016-05-19 JP JP2017560155A patent/JP6674967B2/ja active Active
- 2016-05-19 KR KR1020177036594A patent/KR102220848B1/ko active Active
- 2016-05-19 EA EA201792543A patent/EA035133B1/ru not_active IP Right Cessation
- 2016-05-19 PL PL16724387T patent/PL3298008T3/pl unknown
- 2016-05-19 MY MYPI2017704351A patent/MY192358A/en unknown
- 2016-05-19 RS RS20200051A patent/RS59788B1/sr unknown
-
2017
- 2017-11-08 CL CL2017002822A patent/CL2017002822A1/es unknown
- 2017-11-16 IL IL255718A patent/IL255718B/en active IP Right Grant
-
2019
- 2019-07-03 US US16/503,245 patent/US10836754B2/en active Active
-
2020
- 2020-01-23 CY CY20201100061T patent/CY1122506T1/el unknown
- 2020-10-14 US US17/070,876 patent/US11390615B2/en active Active
-
2022
- 2022-07-01 US US17/810,545 patent/US11834443B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501842A1 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| CY1122506T1 (el) | Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη | |
| PH12016501633B1 (en) | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| CU20170057A7 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
| MX387401B (es) | Producción de 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos a partir de materiales de partida que contienen 2-alquil-4,4-dimetil-1,3-dioxanos. | |
| UA120058C2 (uk) | Пестицидні композиції | |
| MX2019004569A (es) | Metodo para producir 3-alquilsulfanil-2-cloro-n-(1-alquil-1h-tetra zol-5-il)-4-trifluorometilbenzamidas. | |
| PH12016501517A1 (en) | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors | |
| MX2015015562A (es) | Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2. | |
| MX369501B (es) | Proceso para la preparación de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno. | |
| TW201613871A (en) | Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| WO2015001572A3 (en) | Process for the preparation of intermediate of dolutegravir | |
| EP4549538A3 (en) | Improvement in or relating to organic compounds | |
| MX2016013439A (es) | Formas solidas de un compuesto farmaceuticamente activo. | |
| MX2017012661A (es) | Procesos para preparar cloruro de 2-tiofenocarbonilo. | |
| MX2021004996A (es) | Preparacion de 4-metiltetrahidropiranos 2-sustituidos a partir de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos como materiales de partida. | |
| ZA201708645B (en) | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | |
| TN2017000065A1 (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor | |
| IL250469A0 (en) | Process for the production of 1-isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[4,3,1]oxadiazol-2-yl}-1h-indazole oxalate | |
| GR1008554B (el) | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου | |
| IN2013CH05359A (es) | ||
| TW201613870A (en) | Crystalline anti-trichophyton agents and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |